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L877.51 ~ Natural Ni~to~/of Aom¢ Valve O l~ Afte~ 
. . . . . .  MRml Valve Oiil~mt!on 
M Va!un, A, Po~e~= Y ACtOr. Y ShaSta, B Vidr~e, A Sagre C a ~  an~ 
CarO~othorac~c Summon/D~oaglmen~ Rab~ Me~:a~ Center. Be~L~ns~n 
~u~d"  Lfftfe iS known aboul ~ natural h~s'forf at aotlie vane (AV) 
d~ease m plls ~ millrai valve (MV) operalmn. There is lack Of darity 
rngar~ng the ~ fo~ su~g~al lreatment Of rn~ AV disease whde :e~r ig  
the MV. We evak~ted the ~ Of AV ~ ar~ the need for further 
&V sutgeqt arnot~ p{s who undeP~ent MV operet~on (~su~Otomy or 
&~hog~.'One h~n£~! fifty o~e p~ (51 M. 10OF; mean age61 ± 13 yr.'s, 
range 35--89) were to l~ed afte~r MV ope~rat~on fo~ an at, erage period Of 13 
± ? ~.'s (r~mge 1-33). erie hu~d~d that one pts ;~r'~o) hod d~m~a~ heart 
~sease. The AV fu~3~n was assessed by an~ogrep~ and transtharac¢ 
Resu/ts. At the time Of MV operation 66 pts (44%) had AV disease: 7 pts 
(5%1 had ~ aon¢ stenos~ (AS), 64 pis (42%) n~ ~ .,~=~-~.,~on 
(AR) and a s~ng~e I~- (0_7%) moderate AR. At the end Of ~-up  period, 1 I0 
pts (73%) had &V d~ease: 3;2 pts (21%) n~tcl AS, 2 patients (1%) moderate 
AS. 2 pts (1%) severe AS. 96 pts (65%) mt~ AR, 6 pcs (4%) moderate AR 
~nd a smg~e pt (0.7%) severe AR_ AV d~sease had ptogresse£1 s~nd~:andy 
sw~-'e the operation m ordy 2 p~s. Su~ pts (3%1 needed AV reptacement after 
an average penod Of 21 ~ 's (range 15-33). No cfm~¢al factor coutcl ~ent~fy 
¢t~e pts wl~o t ro l l  eventuatly need AV replacement. 
~ n . -  Most o! the pls with rn~ AV d~sease at the t~me of MV oper- 
atie~ c~o not ~ to a severe disease. Thus, it seems that "prophytac~c" 
aortic valve replacement is not ~n(hcated. 
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~ Smoking and Are Associated W'dh the Obesity 
Progression of  Aort ic  Stenosis 
M.V Ngo. JS. Go~ner .  G. Chase. B.J Gersh, RD. F~'c~er, 
D.J. Femicola. Geongetewn Ur~e~ry Hosprtal. Veterans Administration 
Me(lcal Center. Washmglcn D. C , USA 
Backg~un~/: The flaMal history of aod=c stenosis (AS) includes a lafercy 
period followecl by an unp~bte  progress=on. Recent stuclles show an 
assoc, ation between nsk factors for atheroscleresis and the presence of AS. 
We hypothes,ze that atheroscterosrs nsk factors are a~so associated with the 
progression el AS. 
Methods: In a retrospective stu~3y, patients with a d~agnosts of AS IP#- 
continuous wave dappler and a f011ow-up sfuay of at least 6 months were 
included. Independent nsk factorS for the progression of AS were i~ntified 
by stepwise logistic regression analysis. 
Resutts: 123 patients were identified, and complet~ data were o~tained in 
87 patients (mean age 70.7 ¢ 10 yearS, 81% men. and mean foltow-up 2.54 ¢ 
1.6 years). The gradient was considered mild ( < 36 mmHg) in 61% of patients, 
and moderate (36--55 mmHg) in 31%. The mean rate of progression was 
6.3 ± 13 mmHg/year. Of those with mild AS, 36% progressed to moderate 
or severe over 2.9 ± 2.0 years. Independenf clinical factors associated w~th 
a progression of 5 mmHgh/r or greafor included a history of smoking (RR = 
3.06, 95°,o CI = 1.09-861, p = 0034) and a body mass index (kg/m 2) (RR = 
1.16, 95% CI = 1 O3-1.30. p = 0.013). There was an inverse correlation with 
total cholesterol (RR = 0.91 per 10 mg~dl increase. 95% CI = 0.827-0.g99, 
p = 0.0475) only when patients who were taking lipid-lowenng medications 
were included in the analysis. Hypertension, diabetes, age, gender and 
CAD (a history of revasculanzation, myocardial infarction or the presence 
of lesions >50% by catheterization) were not independently associated with 
the progression of AS. 
Conclusion: Body mass index and a history of smoking are independent 
predictors of significant progression of AS defined as -.5 mmHg/year. Inverse 
correlation with cholesterol may reflect cholesterol-lowering treatment as a 
marker for more seve'e disease assoc=alnd with a higher rat0 Of p~;)gress=on~ 
Among the group Of patients with m~ld AS, 36% progressed to read.vile or 
severe during follOw.up 
Venous Thromboembo!lom and 
AntlcolgulM|on 
Wednesday, April 1, 1998, 8;30 a,m.=10:00 a,m, 
Georgia World Congress Center. Room 267W 
8:30 
veln'rhlvem mbol~ AIlioeklled or Not Wilh Pulmomm!!l 
Embolim 
R. Fa~/re FOr PREPIC tnve~tt~ltem: Clfn¢ Samf /~m,  B~n~.or~ France 
Background: Them was a ~ tO ovatuale t~a nsk/~nefrt ratio Of Low 
Molecular Weight Hepafin (LMWH) in the tnn~al tmalrnenl ~f Deep Veto 
Thronll:]~Si~ (DVI-) in presumed h,gh risk pat,c.~S 
, ~ .  LMI~ (Enoxapann, Enos) was cufnl~red to Ul~raclionateo 
Heparm (UFH) m a ran(lomtsed muftcenter trfft~ (PREPIC) in patients with 
vmlogcap~tcatly proven proximal DVT. A f"~:to~al desl~, was unCen~t con- 
comitantly to evaluate vena cava filter versus nc ~dter. Enox (s.c. I mgtkg b =.d) 
and UFH If.v, aPTl'-adiuSted) wer~ gn~m for II~, day~ and followed by oral 
ant~co~ nt  for at least 3 montl'~. Lung scar,~ t± p~tmo~l,y angmgrams) 
were performed s3,'stemai~lly at Cay 1 and .3zy 10. New asymptomalic 
or symptomatic PE at Day 10 was the primary endpoint. Symptomatic PE, 
recurrent DVT, major bleeding arid Death were bl~n~y evaluated at two years. 
~ .~ -<: 400 p~ants were included (195 En ~.,~, 205 UFH). The mean 
v~a-s 72 ylars. 49% of patients had a mltial PIE arid 90% had at least one 
I: .esumed rink faclor of PE./It day 10, new PE rate was 1.6% far Enox and 
42% to~r uFH (p = 0.14). At 2 years, symplomatic PE, recurrent DV'T ancl 
Death rate were sm~lar (3.g% vs 5.7%, 16.6% vs 15.8%, 20.6% vs 211%, 
respec~ve~,). Bleecling was ~ (8-5% vs 12%, NS). 
Con~uso'~.- Enoxapern~ appears at least a~ effective and sate as UFH 
=n the inltia frea~Tierit of proximal DVT associ;iled or not with Pulmonary 
Embessm i,; presumed high ask p'ttient5 
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~ Abbreviated Hospitalization Using a for gv'r Novel 
Low Molecular Weight Heparin, Ardeparln: Results 
of  a Randomized Control led T-ial 
SZ Gotdhaber. R.B Momson, L.L Diren. TH ee, Jr, Bnghamana 
Womens Hc,~at, BostOn, MA, USA 
Backgl~und: Although thelow molecular weight hepann, ardepann, has been 
recently approved for prevention of venous thromboembolism after fatal knee 
replacemerit. It has not been studied previously for treatment of acute deep 
vein thrombosis (DVT). 
Methods: We randomized 80 DVT pat~ts, (diagnosed by venous ultra- 
sound) to either a conventional 5 day hospifahzatmn with continuous mira- 
venous unfract~onated hepann (N = 39) (target PT'r 60-80 seconds) or to a 
2 day hospdalizalion with a low molecular weight hepann (N = 41), ardepilfin 
130 anti.Xa umts/kg suboulaneously twice dally (no laboratory monifomlg), 
until a target fNR of 20-3.0 and a steDle oral dose was achieved with war- 
farm. Patients were evaluated clrmcally with 2 and 6 week off~ce visits and 
uno'en~'ent follow-up venous ultrasound at 6 weeks, 
ResuffS: By ultrasound exammahon, 77% improved compared with base- 
line in the an:tepann group vemus 58% who imp~ with unfraCtionated 
hepann (p = 0.08). One major bleed occurred in each group. Median hospital 
charges were $6.500 aJ~ $?.815, respectively (p - 0.0001) Using a patient 
~tisfact=on sconng system where 1 = Excellent and 2 = Very Good, both 
groups reported an average score of t .3 for the care they recaived. 
Conc/usron. These data ff¢iicate that among properly selected patients, 
an abbrewated hospztahzatron usqng ardepann to manage DVT is effocIwo. 
safe. and much less costIy than conventional therapy. 
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[ -~  Pulmonary Embolism: Diagnosis With Helical 
Computed Tomography Angiography 
SD. Oanadli, A. Vedlard-Baron. F. Bruckert. O. Barre. F Mignon, T. Joseph. 
O. Oubourg, P. Lacombe. Pans V Unn, ersffy .~lmbrotse Pare Hospital. 
France 
Background: Diagnosing pulmon~;'v e .~bohsm (PE] ,e~,,a~ns a major clin=cel 
